JUBLPHARMA Stock Overview
Operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
Jubilant Pharmova Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹724.30 |
52 Week High | ₹800.00 |
52 Week Low | ₹318.75 |
Beta | 1.53 |
11 Month Change | 0.59% |
3 Month Change | 5.69% |
1 Year Change | 94.47% |
33 Year Change | 4.31% |
5 Year Change | 65.23% |
Change since IPO | 757.46% |
Recent News & Updates
Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%
Jan 11Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?
Dec 31Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares
Dec 20Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 08We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt
Nov 27What Kind Of Investors Own Most Of Jubilant Life Sciences Limited (NSE:JUBILANT)?
Nov 17Jubilant Life Sciences Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Nov 06If You Like EPS Growth Then Check Out Jubilant Life Sciences (NSE:JUBILANT) Before It's Too Late
Oct 27Estimating The Fair Value Of Jubilant Life Sciences Limited (NSE:JUBILANT)
Oct 15Does Jubilant Life Sciences' (NSE:JUBILANT) Share Price Gain of 96% Match Its Business Performance?
Oct 03Trade Alert: The Independent Non-Executive Director Of Jubilant Life Sciences Limited (NSE:JUBILANT), Arun Seth, Has Just Spent ₹1.1m Buying 233% More Shares
Sep 21Shareholder Returns
JUBLPHARMA | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -0.2% | -0.9% | -1.3% |
1Y | 94.5% | 46.4% | 43.1% |
Return vs Industry: JUBLPHARMA exceeded the Indian Pharmaceuticals industry which returned 46.4% over the past year.
Return vs Market: JUBLPHARMA exceeded the Indian Market which returned 43.1% over the past year.
Price Volatility
JUBLPHARMA volatility | |
---|---|
JUBLPHARMA Average Weekly Movement | 4.7% |
Pharmaceuticals Industry Average Movement | 5.7% |
Market Average Movement | 6.4% |
10% most volatile stocks in IN Market | 9.6% |
10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: JUBLPHARMA has not had significant price volatility in the past 3 months.
Volatility Over Time: JUBLPHARMA's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1978 | 5,778 | Priyavrat Bhartia | www.jubilantpharmova.com |
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others.
Jubilant Pharmova Limited Fundamentals Summary
JUBLPHARMA fundamental statistics | |
---|---|
Market cap | ₹119.66b |
Earnings (TTM) | ₹5.53b |
Revenue (TTM) | ₹68.48b |
20.8x
P/E Ratio1.7x
P/S RatioIs JUBLPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
JUBLPHARMA income statement (TTM) | |
---|---|
Revenue | ₹68.48b |
Cost of Revenue | ₹21.82b |
Gross Profit | ₹46.65b |
Other Expenses | ₹41.13b |
Earnings | ₹5.53b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 34.75 |
Gross Margin | 68.13% |
Net Profit Margin | 8.07% |
Debt/Equity Ratio | 67.6% |
How did JUBLPHARMA perform over the long term?
See historical performance and comparison